Skip to Content

ACADIA Pharmaceuticals Inc ACAD

Morningstar Rating
$14.91 −0.18 (1.19%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

ACAD is trading at a 422% premium.
Price
$15.14
Fair Value
$23.96
Uncertainty
Very High
1-Star Price
$53.33
5-Star Price
$55.46
Economic Moat
Bbfn
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if ACAD is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$15.09
Day Range
$14.8115.12
52-Week Range
$14.5533.99
Bid/Ask
$14.89 / $14.91
Market Cap
$2.46 Bil
Volume/Avg
1.5 Mil / 1.7 Mil

Key Statistics

Price/Earnings (Normalized)
49.12
Price/Sales
3.06
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

Acadia Pharmaceuticals Inc is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecules drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Growth
Total Number of Employees
610

Comparables

Valuation

Metric
ACAD
VNDA
ITCI
Price/Earnings (Normalized)
49.1282.59
Price/Book Value
5.360.7011.12
Price/Sales
3.062.1112.85
Price/Cash Flow
36.5385.63
Price/Earnings
ACAD
VNDA
ITCI

Financial Strength

Metric
ACAD
VNDA
ITCI
Quick Ratio
1.734.624.50
Current Ratio
2.044.715.12
Interest Coverage
Quick Ratio
ACAD
VNDA
ITCI

Profitability

Metric
ACAD
VNDA
ITCI
Return on Assets (Normalized)
7.16%0.87%−9.15%
Return on Equity (Normalized)
12.48%1.03%−10.98%
Return on Invested Capital (Normalized)
7.68%1.02%−13.47%
Return on Assets
ACAD
VNDA
ITCI
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Vertex Pharmaceuticals Inc
VRTX
JgcvlxbdYvptxq$123.6 Bil
Regeneron Pharmaceuticals Inc
REGN
KnmscstwZszny$113.1 Bil
Moderna Inc
MRNA
PrzlvcryMtzy$55.7 Bil
BioNTech SE ADR
BNTX
VlnjxddtSgt$23.1 Bil
argenx SE ADR
ARGX
DzyszzvzThbg$22.4 Bil
Alnylam Pharmaceuticals Inc
ALNY
KngwmvljWzvjcx$20.2 Bil
Biomarin Pharmaceutical Inc
BMRN
FxlxvlrQrxxt$16.0 Bil
United Therapeutics Corp
UTHR
PmtfnwwKbdgv$12.8 Bil
Incyte Corp
INCY
RswwmtryXkjlkz$12.3 Bil
Royalty Pharma PLC Class A
RPRX
CpsfjhkyzdTrkrq$12.3 Bil

Sponsor Center